Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Financing Activities (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash from Financing Activities for 7 consecutive years, with -$99.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to -$99.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $137.2 million for FY2025, 35.61% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$99.9 million at Soleno Therapeutics, down from $218.2 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $218.2 million in Q3 2025, with the low at -$99.9 million in Q4 2025.